Navigation Links
Highlights from BioMarin's Research & Development Day
Date:12/8/2011

>

  • Successful Type C meeting with FDA
  • Reduction in Phe is an acceptable primary endpoint for Phase III
  • Pivotal trial can be conducted in diet non compliant patients
  • Phase 2 Update
  • Weekly dosing (Part A and B): Good safety profile and substantial Phe reduction achieved in the majority of patients continuing in the study at a median maintenance dose of 1.0 mg/kg/week
  • Daily dosing (Part C): Initial rapid Phe reduction achieved in all patients but not sustained in the majority of patients; joint pain, fever and/or rash reliably ten days after study start
  • Initiating Part D of Phase 2 study to find the quickest and safest induction dosing regimen to an efficacious maintenance dose.  The optimal chronic regimen will be one subcutaneous injection per day.
  • Immunology Update
  • A daily dosing induction schedule leads to higher levels of anti PEG IgM titers and both higher and earlier PAL IgG titers compared to weekly dosing
  • Ways to attenuate the hypersensitivity reactions: Limit dosing when IgM responses are highest and titrate to efficacious doses once the IgG response has developed
  • Some patients do not mount a robust IgM Response to PEG and appear to have sustained efficacy and good tolerance
  • BMN-673 for Genetically-Defined Cancers

  • Dose escalation in Phase 1/2 study in solid tumors continuing after 5 steps (25-400 μg/once per day)
  • PK analysis is ongoing: Preliminary data indicate long terminal half-life
  • Once daily oral dosing is feasible
  • Preliminary results are encouraging in terms of toxicity and signs of efficacy
  • BMN-111 for Achondroplasia

  • Demonstrated benefits in moderately and severely affected animal models
  • Positive therapeutic index predicted in vivo
  • Phase 1 clinical trial in healthy volunteers to begin 1Q 2012
  • Phase 2 proof of concept trial in affected pedi
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
    6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
    7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
    8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
    9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
    10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... , March 3, 2015 Although lung ... the world, there are only 18 drugs in the ... Almita and Avastin are nearing their patent expiry in ... therapeutics market offers vast potential that drug manufacturers are ... treatment of small cell lung cancer (SCLC) and non-small ...
    (Date:3/3/2015)... , March 3, 2015 ImmunoCellular Therapeutics, ... Andrew Gengos , Chief Executive Officer of ImmunoCellular, will ... 27 th Annual ROTH Conference on Tuesday, March ... Hotel, Laguna Niguel , CA.   ... the ROTH presentation, please log on through a link ...
    (Date:3/3/2015)... , March 3, 2015 Chrono Therapeutics ... an investment by Rock Health , the leading ... of Chrono,s SmartStop™ programmable transdermal drug delivery system and ... Smoking kills more than 500,000 Americans each year, ... in the United States . Of ...
    Breaking Medicine Technology:Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
    ... N.J., Sept. 28 Laureate Pharma, Inc., ... company, today announced the appointment of Steven ... Mr. Johnson will be responsible for Laureate,s ... business development and project management, supporting the ...
    ... JUNCTION, N.J., Sept. 28 Tamir Biotechnology, Inc. ... Corporation) announced today that scientists supported by the ... reported test results confirming two of our lead ... cell culture and plaque reduction assay (the gold ...
    Cached Medicine Technology:Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
    (Date:3/3/2015)... Prophecy Healthcare®, Inc., the nation's ... testing, is now conducting dedicated research to expand ... of acquiring the exam rights and Intellectual Property ... the research will soon create more health care ... healthcare staffing organizations and more. , ...
    (Date:3/3/2015)... 2015 Extend Nutrition, a leading nutritional snack ... of calories consumed at the next meal by an average ... are no lifestyle changes needed and no program to abide ... , The starter kit contains 60 servings of nutritional bars, ... protein, fiber, healthy fat and complex carbohydrates that helps to ...
    (Date:3/3/2015)... 03, 2015 Getting to the truth of ... and well-being are at stake. So when it comes to ... move about pain-free – it’s vital to separate fact from ... resource, according to Sridhar Yalamanchili, PT, MSPT, and Director of ... A September 2014 nationwide survey by the American Physical Therapy ...
    (Date:3/3/2015)... (PRWEB) March 03, 2015 Human ... that it’s offering a new master health insurance plan ... its clients with a group platform removing potential cost ... Master Health Plan has been in effect since January ... clients with much need medical cost savings. , The ...
    (Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans and stand-alone ... changes to sift through as a result of CMS’s ... Feb. 20. The potential pay changes alone are tough ... type and location of the plan’s membership. But there ... before CMS issues the final notice and when 2016 ...
    Breaking Medicine News(10 mins):Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:HCBR Group Offers Master Healthcare Plan through Humana 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2
    ... PORTLAND, Ore. Researchers at Oregon Health & Science University,s ... women at high-risk for ovarian cancer who also want to ... which serve as the "breeding ground" for ovarian cancer, may ... would be a vast improvement over the current prevention strategy ...
    ... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) ... not to mention the Grim Reaper, a new study from ... go shopping daily live longer than their less shopping-prone peers. ... women, according to the study, which was published recently in ...
    ... TORONTO, Ont., April 7, 2011 Virtual reality and other ... according to research from St. Michael,s Hospital. Patients ... up to five times more likely to show improvements in ... "Virtual reality gaming is a promising and potentially ...
    ... doctors more accountable for health care quality, more attention must ... to evaluate caregivers, says a prominent Johns Hopkins patient safety ... Health Affairs , Peter J. Pronovost, M.D., Ph.D., a ... Hopkins University School of Medicine, argues that as the desire ...
    ... Biology and Medicine is pleased to announce the 2011 ... $500 travel grant for undergraduate/ graduate students and/or individuals ... members of the Society to attend the Experimental Biology ... of their research work which were evaluated by a ...
    ... three-year follow-up study of patients in the Hepatitis ... revealed that increased mortality among patients with advanced ... was attributed to non-liver related causes and occurred ... to this excess mortality was evident to researchers, ...
    Cached Medicine News:Health News:Ovarian cancer finding may be a 'win-win' for at-risk women who wish to have a family 2Health News:'Retail Therapy' Might Really Work 2Health News:'Retail Therapy' Might Really Work 3Health News:Video games effective treatment for stroke patients: study 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 3Health News:SEBM Young Investigator Awards for 2011 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 3
    ... automated patient ID verification and laboratory specimen labeling ... of the phlebotomist or nurse, the identity of ... proper verification is made, a bar coded sample ... Its unique design simplifies and eliminates the interface ...
    ... Bridge™ Specimen Collections, a Cerner ... for specimen identification and collection. The ... of the specimen collections process by ... and clinical information system integration to ...
    ... bar-code medication administration solution that safely automates ... bar-code technology. Caregivers use a wireless bar-code ... to verify that the right patient receives ... in the right dosage via the right ...
    ... Korchek Technologies CareChek ... employs barcode technology, Windows ... with integrated scanners (to ... at the bedside) and ...
    Medicine Products: